MERRIMACK PHARMACEUTICALS INC

Overview

• IndustryPharmaceutical Preparations¹
• HeadquartersCambridge, Massachusetts¹
• Incorporated inDE²
• Business addressOne Broadway, 14Th Floor, Cambridge, Ma 02142²
• Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

We are a biopharmaceutical company based in Cambridge, Massachusetts that is entitled to receive up to $450.0 million in contingent milestone payments related to our sale of ONIVYDE® to Ipsen S.A., or Ipsen, in April 2017 and up to $54.5 million in contingent milestone payments related to our sale of MM-121 and MM-111 to Elevation Oncology, Inc. (formerly known as 14ner Oncology, Inc.), or Elevation, in July 2019. We do not have any ongoing research or development activities and are seeking potential acquirers for our remaining preclinical and clinical assets. We do not have any employees and instead use external consultants for the operation of our company.³ From its latest annual report

Corporate structure

MERRIMACK PHARMACEUTICALS INC sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What MERRIMACK PHARMACEUTICALS INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

Leadership

Who has led MERRIMACK PHARMACEUTICALS INC, and when. Pick a name to see everywhere that person has worked.

• Chief executive officerRobert J. Mulroy Feb 1, 2012 to Feb 10, 2016¹⁵
• PresidentGary L. Crocker Oct 21, 2019 to Oct 21, 2019¹⁶
• PresidentRobert J. Mulroy Feb 1, 2012 to Feb 10, 2016¹⁵
• Chief financial officerJean M. Franchi Aug 28, 2017 to Dec 13, 2018¹⁷
• Chief financial officerYasir B. Al-Wakeel Aug 13, 2015 to Feb 10, 2016¹⁸
• Chief financial officerWilliam A. Sullivan Feb 1, 2012 to Jul 17, 2015¹⁹

Timeline

1. May 10, 20248-K Shareholder vote; Regulation FD disclosure⁴⁸
2. May 9, 20248-K Regulation FD disclosure⁴⁹
3. Apr 30, 20248-K Listing notice or transfer; Regulation FD disclosure⁵⁰
4. Mar 27, 20248-K Regulation FD disclosure⁵¹
5. Mar 7, 20248-K Regulation FD disclosure⁵²
6. Feb 13, 20248-K Regulation FD disclosure⁵³
7. Nov 2, 20238-K Regulation FD disclosure⁵⁴
8. Aug 3, 20238-K Regulation FD disclosure⁵⁵
9. Jun 7, 20238-K Shareholder vote⁵⁶
10. May 4, 20238-K Regulation FD disclosure⁵⁷
11. Mar 9, 20238-K Regulation FD disclosure⁵⁸
12. Dec 5, 20228-K Entered a material agreement; Change to shareholders' rights; Regulation FD disclosure⁵⁹
13. Feb 1, 2012New chief executive Robert J. Mulroy becomes CEO¹⁵

Filings

119 filings to the SEC since October 2021: 4 annual reports, 8 quarterly reports, 21 major events, 58 insider forms, 12 large holders, 16 other. The latest 20:

1. May 20, 202415-12G EDGAR
2. May 15, 202410-Q EDGAR
3. May 10, 202425 EDGAR
4. May 10, 20248-K EDGAR
5. May 9, 2024DEFA14A EDGAR
6. May 9, 20248-K EDGAR
7. Apr 30, 2024DEFA14A EDGAR
8. Apr 30, 20248-K EDGAR
9. Apr 1, 2024DEFR14A EDGAR
10. Mar 27, 2024DEFA14A EDGAR
11. Mar 27, 20248-K EDGAR
12. Mar 22, 2024DEFA14A EDGAR
13. Mar 21, 2024DEF 14A EDGAR
14. Mar 21, 202410-K/A EDGAR
15. Mar 7, 2024425 EDGAR
16. Mar 7, 20248-K EDGAR
17. Mar 7, 2024SC 13G/A EDGAR
18. Mar 7, 202410-K EDGAR
19. Mar 5, 2024PRE 14A EDGAR
20. Feb 22, 2024SCHEDULE 13G EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

81 open-market trades by officers, directors and large owners since October 2021: 80 buys and 1 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• ADAR1 Partners, LPSCHEDULE 13G, 1 filing Feb 22, 2024⁶⁰
• 22NW Fund, LPSC 13G/A, 2 filings Feb 13, 2023 to Feb 14, 2024⁶¹
• Newtyn Management, LLCSC 13D/A, 1 filing Jan 25, 2024⁶²
• Western Standard LLCSC 13D/A, 2 filings Aug 14, 2023 to Dec 13, 2023⁶³
• Point72 Asset Management, L.P.SC 13G/A, 2 filings Aug 4, 2022 to Feb 14, 2023⁶⁴
• 22NW, LPSC 13G/A, 1 filing Feb 14, 2022⁶⁵
• Nantahala Capital Management, LLCSC 13G/A, 1 filing Feb 14, 2022⁶⁶

SEC filer profile

How MERRIMACK PHARMACEUTICALS INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARMERRIMACK PHARMACEUTICALS INC¹
• CIK0001274792
• Filer statusNon-accelerated filer<br>smaller reporting company¹
• Incorporated inDelaware¹
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business addressOne Broadway, 14Th Floor, Cambridge, MA 02142¹
• Phone617-441-1000¹
• Shares outstanding14,788,369 as of May 13, 2024¹²
• Public float$129.7M as of Jun 30, 2023⁹
• On EDGAR sinceDec 29, 2003¹
• Filings807 in all: 4 (357), 8-K (126), 3 (39), 10-Q (37), SC 13G/A (35), DEFA14A (25), SC 13G (19), UPLOAD (16)¹
  All 49 form types

  SC 13D/A (15), CORRESP (14), 10-K (13), DEF 14A (12), CT ORDER (9), S-8 (9), 4/A (7), EFFECT (5), PRE 14A (5), REGDEX (5), 424B5 (4), PRER14A (4), S-1/A (4), 10-K/A (3), 5 (3), ARS (3), DFAN14A (3), S-3 (3), SC 13D (3), SC TO-I/A (3), CERTNAS (2), FWP (2), POS AM (2), PREC14A (2), PRRN14A (2), 15-12G (1), 25 (1), 305B2 (1), 424B4 (1), 425 (1), 8-A12B (1), 8-A12G (1), 8-K/A (1), D (1), DEFM14A (1), DEFR14A (1), PREM14A (1), S-1 (1), S-3ASR (1), SC TO-I (1), SCHEDULE 13G (1)

• Latest filingsAnnual report (10-K) Mar 7, 2024
  Quarterly report (10-Q) May 15, 2024
  Proxy statement (DEF 14A) Mar 21, 2024
  Latest 8-K (8-K) May 10, 2024